PEDIATRIX MEDICAL GROUP INC (MD) Stock Fundamental Analysis

NYSE:MD • US58502B1061

19.85 USD
-0.01 (-0.05%)
At close: Feb 27, 2026
19.85 USD
0 (0%)
After Hours: 2/27/2026, 8:17:23 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

MD gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 101 industry peers in the Health Care Providers & Services industry. MD scores excellent on profitability, but there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on MD. This makes MD very considerable for value investing!


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • MD had positive earnings in the past year.
  • In the past year MD had a positive cash flow from operations.
  • In multiple years MD reported negative net income over the last 5 years.
  • MD had a positive operating cash flow in each of the past 5 years.
MD Yearly Net Income VS EBIT VS OCF VS FCFMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M -1B

1.2 Ratios

  • MD has a better Return On Assets (7.36%) than 89.11% of its industry peers.
  • MD's Return On Equity of 19.10% is amongst the best of the industry. MD outperforms 86.14% of its industry peers.
  • With a decent Return On Invested Capital value of 9.88%, MD is doing good in the industry, outperforming 79.21% of the companies in the same industry.
  • MD had an Average Return On Invested Capital over the past 3 years of 8.21%. This is in line with the industry average of 9.08%.
  • The last Return On Invested Capital (9.88%) for MD is above the 3 year average (8.21%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 7.36%
ROE 19.1%
ROIC 9.88%
ROA(3y)0.01%
ROA(5y)1.53%
ROE(3y)-0.32%
ROE(5y)4.22%
ROIC(3y)8.21%
ROIC(5y)7.97%
MD Yearly ROA, ROE, ROICMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80 -100

1.3 Margins

  • Looking at the Profit Margin, with a value of 8.64%, MD belongs to the top of the industry, outperforming 91.09% of the companies in the same industry.
  • MD's Profit Margin has improved in the last couple of years.
  • The Operating Margin of MD (12.07%) is better than 84.16% of its industry peers.
  • In the last couple of years the Operating Margin of MD has grown nicely.
Industry RankSector Rank
OM 12.07%
PM (TTM) 8.64%
GM N/A
OM growth 3Y5.99%
OM growth 5Y4.02%
PM growth 3Y36.96%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MD Yearly Profit, Operating, Gross MarginsMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • MD has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • The number of shares outstanding for MD has been reduced compared to 1 year ago.
  • The number of shares outstanding for MD has been reduced compared to 5 years ago.
  • MD has a better debt/assets ratio than last year.
MD Yearly Shares OutstandingMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
MD Yearly Total Debt VS Total AssetsMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2.2 Solvency

  • An Altman-Z score of 2.04 indicates that MD is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 2.04, MD is in line with its industry, outperforming 51.49% of the companies in the same industry.
  • MD has a debt to FCF ratio of 2.36. This is a good value and a sign of high solvency as MD would need 2.36 years to pay back of all of its debts.
  • MD has a Debt to FCF ratio of 2.36. This is in the better half of the industry: MD outperforms 77.23% of its industry peers.
  • A Debt/Equity ratio of 0.66 indicates that MD is somewhat dependend on debt financing.
  • The Debt to Equity ratio of MD (0.66) is comparable to the rest of the industry.
  • Although MD does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF 2.36
Altman-Z 2.04
ROIC/WACC1.24
WACC7.94%
MD Yearly LT Debt VS Equity VS FCFMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.3 Liquidity

  • MD has a Current Ratio of 1.66. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.66, MD is in the better half of the industry, outperforming 65.35% of the companies in the same industry.
  • A Quick Ratio of 1.66 indicates that MD should not have too much problems paying its short term obligations.
  • The Quick ratio of MD (1.66) is better than 69.31% of its industry peers.
Industry RankSector Rank
Current Ratio 1.66
Quick Ratio 1.66
MD Yearly Current Assets VS Current LiabilitesMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 36.24% over the past year.
  • MD shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 10.01% yearly.
  • Looking at the last year, MD shows a decrease in Revenue. The Revenue has decreased by -4.92% in the last year.
  • MD shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.99% yearly.
EPS 1Y (TTM)36.24%
EPS 3Y6.72%
EPS 5Y10.01%
EPS Q2Q%-1.96%
Revenue 1Y (TTM)-4.92%
Revenue growth 3Y-0.99%
Revenue growth 5Y1.99%
Sales Q2Q%-1.71%

3.2 Future

  • The Earnings Per Share is expected to grow by 1.48% on average over the next years.
  • MD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.60% yearly.
EPS Next Y10.99%
EPS Next 2Y8.08%
EPS Next 3Y2.62%
EPS Next 5Y1.48%
Revenue Next Year2.7%
Revenue Next 2Y2.49%
Revenue Next 3Y4.56%
Revenue Next 5Y4.6%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MD Yearly Revenue VS EstimatesMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1B 2B 3B
MD Yearly EPS VS EstimatesMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 9.78, which indicates a very decent valuation of MD.
  • MD's Price/Earnings ratio is rather cheap when compared to the industry. MD is cheaper than 93.07% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of MD to the average of the S&P500 Index (27.07), we can say MD is valued rather cheaply.
  • With a Price/Forward Earnings ratio of 8.81, the valuation of MD can be described as very reasonable.
  • Based on the Price/Forward Earnings ratio, MD is valued cheaply inside the industry as 93.07% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 28.05. MD is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 9.78
Fwd PE 8.81
MD Price Earnings VS Forward Price EarningsMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MD indicates a rather cheap valuation: MD is cheaper than 88.12% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, MD is valued cheaper than 90.10% of the companies in the same industry.
Industry RankSector Rank
P/FCF 6.75
EV/EBITDA 6.63
MD Per share dataMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of MD may justify a higher PE ratio.
PEG (NY)0.89
PEG (5Y)0.98
EPS Next 2Y8.08%
EPS Next 3Y2.62%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for MD!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PEDIATRIX MEDICAL GROUP INC

NYSE:MD (2/27/2026, 8:17:23 PM)

After market: 19.85 0 (0%)

19.85

-0.01 (-0.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-19
Earnings (Next)05-04
Inst Owners98.9%
Inst Owner Change1.26%
Ins Owners1.87%
Ins Owner Change-1.02%
Market Cap1.70B
Revenue(TTM)1.91B
Net Income(TTM)165.39M
Analysts78.67
Price Target21.93 (10.48%)
Short Float %3.33%
Short Ratio4.04
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.87%
Min EPS beat(2)-9.94%
Max EPS beat(2)39.68%
EPS beat(4)3
Avg EPS beat(4)20.9%
Min EPS beat(4)-9.94%
Max EPS beat(4)39.68%
EPS beat(8)7
Avg EPS beat(8)17.99%
EPS beat(12)7
Avg EPS beat(12)8.59%
EPS beat(16)8
Avg EPS beat(16)5.12%
Revenue beat(2)1
Avg Revenue beat(2)-0.49%
Min Revenue beat(2)-1.41%
Max Revenue beat(2)0.42%
Revenue beat(4)1
Avg Revenue beat(4)-1.1%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)0.42%
Revenue beat(8)2
Avg Revenue beat(8)-1.43%
Revenue beat(12)2
Avg Revenue beat(12)-2.28%
Revenue beat(16)2
Avg Revenue beat(16)-2.52%
PT rev (1m)-5.15%
PT rev (3m)-5.15%
EPS NQ rev (1m)-0.55%
EPS NQ rev (3m)-0.55%
EPS NY rev (1m)0%
EPS NY rev (3m)19.44%
Revenue NQ rev (1m)-1.44%
Revenue NQ rev (3m)-1.44%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.1%
Valuation
Industry RankSector Rank
PE 9.78
Fwd PE 8.81
P/S 0.89
P/FCF 6.75
P/OCF 6.29
P/B 1.97
P/tB N/A
EV/EBITDA 6.63
EPS(TTM)2.03
EY10.23%
EPS(NY)2.25
Fwd EY11.35%
FCF(TTM)2.94
FCFY14.82%
OCF(TTM)3.16
OCFY15.9%
SpS22.29
BVpS10.08
TBVpS-4.79
PEG (NY)0.89
PEG (5Y)0.98
Graham Number21.46
Profitability
Industry RankSector Rank
ROA 7.36%
ROE 19.1%
ROCE 12.93%
ROIC 9.88%
ROICexc 13.71%
ROICexgc 1686.9%
OM 12.07%
PM (TTM) 8.64%
GM N/A
FCFM 13.2%
ROA(3y)0.01%
ROA(5y)1.53%
ROE(3y)-0.32%
ROE(5y)4.22%
ROIC(3y)8.21%
ROIC(5y)7.97%
ROICexc(3y)10.42%
ROICexc(5y)9.77%
ROICexgc(3y)618.91%
ROICexgc(5y)394.62%
ROCE(3y)10.75%
ROCE(5y)10.43%
ROICexgc growth 3Y208.98%
ROICexgc growth 5Y85.34%
ROICexc growth 3Y17.7%
ROICexc growth 5Y11.82%
OM growth 3Y5.99%
OM growth 5Y4.02%
PM growth 3Y36.96%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.85
Health
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF 2.36
Debt/EBITDA 2.26
Cap/Depr 84.57%
Cap/Sales 0.96%
Interest Coverage 6.72
Cash Conversion 107.19%
Profit Quality 152.75%
Current Ratio 1.66
Quick Ratio 1.66
Altman-Z 2.04
F-Score8
WACC7.94%
ROIC/WACC1.24
Cap/Depr(3y)81.68%
Cap/Depr(5y)85.74%
Cap/Sales(3y)1.24%
Cap/Sales(5y)1.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.24%
EPS 3Y6.72%
EPS 5Y10.01%
EPS Q2Q%-1.96%
EPS Next Y10.99%
EPS Next 2Y8.08%
EPS Next 3Y2.62%
EPS Next 5Y1.48%
Revenue 1Y (TTM)-4.92%
Revenue growth 3Y-0.99%
Revenue growth 5Y1.99%
Sales Q2Q%-1.71%
Revenue Next Year2.7%
Revenue Next 2Y2.49%
Revenue Next 3Y4.56%
Revenue Next 5Y4.6%
EBIT growth 1Y25.81%
EBIT growth 3Y4.93%
EBIT growth 5Y6.1%
EBIT Next Year16.32%
EBIT Next 3Y7%
EBIT Next 5YN/A
FCF growth 1Y36.89%
FCF growth 3Y22.56%
FCF growth 5Y7.52%
OCF growth 1Y31.23%
OCF growth 3Y17.54%
OCF growth 5Y5.79%

PEDIATRIX MEDICAL GROUP INC / MD FAQ

What is the ChartMill fundamental rating of PEDIATRIX MEDICAL GROUP INC (MD) stock?

ChartMill assigns a fundamental rating of 6 / 10 to MD.


What is the valuation status for MD stock?

ChartMill assigns a valuation rating of 8 / 10 to PEDIATRIX MEDICAL GROUP INC (MD). This can be considered as Undervalued.


How profitable is PEDIATRIX MEDICAL GROUP INC (MD) stock?

PEDIATRIX MEDICAL GROUP INC (MD) has a profitability rating of 7 / 10.


What are the PE and PB ratios of PEDIATRIX MEDICAL GROUP INC (MD) stock?

The Price/Earnings (PE) ratio for PEDIATRIX MEDICAL GROUP INC (MD) is 9.78 and the Price/Book (PB) ratio is 1.97.